Zydus Lifesciences Ltd
ZYDUSLIFEBSE 532321PharmaceuticalsMkt cap ₹1,14,239 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹8,017 Cr
YoY +22.0%QoQ +5.7%
Net profit · Q1 FY27
₹990 Cr
YoY -34.9%QoQ -26.2%
Net margin · Q1 FY27
12.3%
-10.8 pts vs Q1 FY26
Net profit · FY26
₹5,124 Cr
YoY +9.6%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 8,017 | 7,587 | 6,865 | 6,123 | 6,574 | +22.0% |
| Other income | 106 | 134 | 111 | 109 | 155 | -31.5% |
| Total income | 8,123 | 7,721 | 6,976 | 6,232 | 6,729 | +20.7% |
| Profit before tax | 1,307 | 1,660 | 1,353 | 1,687 | 1,921 | -32.0% |
| Tax | 354 | 318 | 388 | 454 | 434 | -18.4% |
| Net profit | 990 | 1,341 | 1,023 | 1,239 | 1,521 | -34.9% |
| Net margin | 12.3% | 17.7% | 14.9% | 20.2% | 23.1% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 27,148 | 23,242 | 19,547 | 17,237 | 15,265 | +16.8% |
| Other income | 510 | 270 | 284 | 187 | 225 | +89.1% |
| Total income | 27,658 | 23,511 | 19,832 | 17,424 | 15,490 | +17.6% |
| Profit before tax | 6,621 | 6,027 | 4,809 | 2,590 | 2,838 | +9.9% |
| Tax | 1,595 | 1,412 | 978 | 588 | 512 | +12.9% |
| Net profit | 5,124 | 4,673 | 3,973 | 2,092 | 4,618 | +9.6% |
| Net margin | 18.9% | 20.1% | 20.3% | 12.1% | 30.3% |
BIC's take
We haven't covered Zydus Lifesciences Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:24 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.